{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:26:16Z","timestamp":1765887976009},"reference-count":58,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"U.S. Department of Education Office for English Language Acquisition National Professional Development Grant","award":["T365Z120015"],"award-info":[{"award-number":["T365Z120015"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2018,4,13]]},"DOI":"10.1080\/14656566.2018.1450866","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T11:11:35Z","timestamp":1521544295000},"page":"589-596","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Next generation fixed dose combination pharmacotherapies for treating HIV"],"prefix":"10.1080","volume":"19","author":[{"given":"Margaret R.","family":"Caplan","sequence":"first","affiliation":[{"name":"Division of HIV Medicine, Department of Internal Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Daar","sequence":"additional","affiliation":[{"name":"Division of HIV Medicine, Department of Internal Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katya C.","family":"Corado","sequence":"additional","affiliation":[{"name":"Division of HIV Medicine, Department of Internal Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371102"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.12.930"},{"key":"CIT0003","volume-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2017"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8900"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-10-200311180-00008"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200403010-00006"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1086\/313855"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1086\/596482"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu046"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2011.011292"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0081"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170661"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328340a209"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1889"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19765"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506816"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002015"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002357"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.1.21579"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.1.21708"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105243"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200407010-00007"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2015.08.002"},{"key":"CIT0024","unstructured":"European AIDS Clinical Society. EACS Guidelines version 9.0. 2017 Oct. [cited 2018 Feb 23]. Available from: http:\/\/www.eacsociety.org\/files\/guidelines_9.0-english.pdf."},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.035"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000225"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"issue":"4","key":"CIT0029","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3018(16)00024-2","volume":"3","author":"Gallant JE","year":"2016","journal-title":"Lancet HIV"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1288720"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000908"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30031-0"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000618"},{"key":"CIT0034","volume-title":"16th European AIDS Conference","author":"Eron J","year":"2017"},{"issue":"1","key":"CIT0035","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","volume":"5","author":"Orkin C","year":"2018","journal-title":"Lancet HIV"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04201-14"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02650-15"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19532"},{"key":"CIT0039","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Gatell J","year":"2016"},{"key":"CIT0040","volume-title":"International AIDS Society Conference","author":"Squires KE","year":"2017"},{"key":"CIT0041","volume-title":"Conference on Retroviruses and Opporunistic Infections (CROI)","author":"Molina JM","year":"2017"},{"key":"CIT0042","unstructured":"Dutrebis (lamivudine and raltegravir) tablet. FDA Drug Approvals and Databases. 2016. [cited 2017 Dec 8]. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206510Orig1s000TOC.cfm."},{"key":"CIT0043","doi-asserted-by":"crossref","unstructured":"Cahn P, Kaplan R, Sax PE, et al. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017;4(11):e486\u2013494.","DOI":"10.1097\/QAI.0000000000001723"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ981"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.01.21678"},{"key":"CIT0048","volume-title":"9th IAS Conference on HIV Science","author":"Figueroa MI","year":"2017"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1131"},{"key":"CIT0050","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Joly V","year":"2017"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30016-4"},{"issue":"10107","key":"CIT0053","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax PE","year":"2017","journal-title":"Lancet"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"CIT0055","volume-title":"International AIDS Society Conference","author":"Aboud M","year":"2017"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006275"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12562"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1728"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2018.1450866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T10:57:55Z","timestamp":1598698675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2018.1450866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,4,13]]}},"alternative-id":["10.1080\/14656566.2018.1450866"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2018.1450866","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}